Published in JBI Evid Synth on May 01, 2020
Industry sponsorship and research outcome. Cochrane Database Syst Rev (2012) 7.44
Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med (2009) 5.15
Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med (2008) 3.57
Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med (2013) 2.49
Financial ties and conflicts of interest between pharmaceutical and tobacco companies. JAMA (2002) 2.43
Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Perspect (2013) 2.21
Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev (2010) 2.11
Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev (2014) 2.10
Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ (2012) 1.58
CONSORT 2010. Lancet (2010) 1.50
Medicaid drug selection committees and inadequate management of conflicts of interest. JAMA Intern Med (2013) 1.39
Author's specialty and conflicts of interest contribute to conflicting guidelines for screening mammography. J Clin Epidemiol (2012) 1.28
Priority medicines for maternal and child health: a global survey of national essential medicines lists. PLoS One (2012) 1.19
Association of trial registration with the results and conclusions of published trials of new oncology drugs. Trials (2009) 1.19
The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev (2013) 1.12
Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ (2013) 1.07
Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala. Global Health (2012) 1.05
Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes. Public Health Nutr (2009) 0.98
Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Med (2009) 0.93
Strategies for obtaining unpublished drug trial data: a qualitative interview study. Syst Rev (2013) 0.88
Interventions for tobacco use cessation in people in treatment for or recovery from substance abuse. Cochrane Libr (2012) 0.87
Factors associated with results and conclusions of trials of thiazolidinediones. PLoS One (2009) 0.86
The beliefs of nurses who were involved in a whistleblowing event. J Adv Nurs (2002) 0.85
Tobacco industry research and protection of human subjects: a case study of R. J. Reynolds. Nicotine Tob Res (2007) 0.83
Interactions between non-physician clinicians and industry: a systematic review. PLoS Med (2013) 0.83
Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia. BMC Health Serv Res (2012) 0.81
Review of the quality of pediatric medications in developing countries. J Pharm Sci (2013) 0.81
Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors. Chiropr Osteopat (2010) 0.79
A clearer view of evidence in treating macular degeneration: off-label policies and independent research. Cochrane Database Syst Rev (2014) 0.78
Regulatory agencies hold the key to improving Cochrane reviews of drugs. Cochrane Database Syst Rev (2015) 0.77
Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder. Psychother Psychosom (2017) 0.76
Clarification of study and citation. Arch Intern Med (2007) 0.75
Instruments for assessing risk of bias and other methodological criteria: Krauth et al. Respond. Environ Health Perspect (2014) 0.75
Systematic reviews: perhaps "the answer to policy makers' prayers"? Environ Health Perspect (2014) 0.75
Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev (2016) 0.75
The Cochrane Library Oversight Committee. Cochrane Database Syst Rev (2011) 0.75
Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme. Int J Pharm Pract (2010) 0.75